Edwards Lifesciences (EW) Share-based Compensation (2009 - 2026)

Edwards Lifesciences has reported Share-based Compensation for 18 years, with the latest figure at $42.2 million in Q2 2026.

• On a quarterly basis, Share-based Compensation rose 12.53% year-over-year to $42.2 million in Q2 2026; TTM through Jun 2026 was $168.0 million, a 10.89% increase from a year earlier, with the FY2025 full-year figure at $158.1 million, down 2.59% from the prior year.
• Share-based Compensation was $42.2 million for Q2 2026 at Edwards Lifesciences, down from $45.4 million in the prior quarter.
• The five-year high for Share-based Compensation was $45.4 million in Q1 2026, with the low at $27.9 million in Q4 2022.
• Average Share-based Compensation over 5 years is $37.5 million, with a median of $38.2 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation grew 29.14% in 2024, then declined 14.58% in 2025.
• Over 5 years, Share-based Compensation stood at $27.9 million in 2022, then grew by 9.32% to $30.5 million in 2023, then grew by 3.93% to $31.7 million in 2024, then rose by 23.66% to $39.2 million in 2025, then increased by 7.65% to $42.2 million in 2026.
• The last three Share-based Compensation figures came in at $42.2 million (Q2 2026), $45.4 million (Q1 2026), and $39.2 million (Q4 2025), per Business Quant data.